PAPER Baño Otalora B, Popovic N, Gambini J, Popovic M, Viña J, Bonet-Costa V, Reiter RJ, Camello PJ, Rol MÁ, Madrid JA

Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon.

Chronobiol Int. 2012 Aug;29(7):822-34. PubMed: 22823866

PAPER Dobarro M, Orejana L, Aguirre N, Ramírez MJ

Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model.

Neuropharmacology. 2013 Jan;64(1):137-44. PubMed: 22824191

PAPER van der Flier WM, Cordonnier C

Microbleeds in vascular dementia: Clinical aspects.

Exp Gerontol. 2012 Nov;47(11):853-7. PubMed: 22824542

PAPER Correia SC, Santos RX, Cardoso S, Carvalho C, Candeias E, Duarte AI, Plácido AI, Santos MS, Moreira PI

Alzheimer disease as a vascular disorder: Where do mitochondria fit?

Exp Gerontol. 2012 Nov;47(11):878-86. PubMed: 22824543

PAPER Sozio P, Rapino M, Di Valerio V, Laserra S, Pacella S, Di Stefano A, Cataldi A

pPKCα-mediated effect on in vitro Aβ production in response to gamma secretase inhibitor LY411575 in rat CTXTNA2 astrocytes.

J Biol Regul Homeost Agents. 2012 Apr-Jun;26(2):245-51. PubMed: 22824752

PAPER Honig LS, Kang MS, Schupf N, Lee JH, Mayeux R

Association of Shorter Leukocyte Telomere Repeat Length With Dementia and Mortality.

Arch Neurol. 2012 Jul 23;:1-8. PubMed: 22825311

PAPER Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS

Pathologic Accumulation of α-Synuclein and Aβ in Parkinson Disease Patients With Dementia.

Arch Neurol. 2012 Jul 23;:1-6. PubMed: 22825369

PAPER Pressman P, Gottfried JA

Journal Club: a randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.

Neurology. 2012 Jul 24;79(4):e33-6. PubMed: 22826548

Rafal Smigrodzki on No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers

COMMENT We have to roundly reject approaches based on the amyloid hypothesis. They lead to failures in all attempts, from immunotherapy to secretase inhibitors to COX inhibitors. Changing of amyloid concentration in the CSF is not a measure of "disease modif

PAPER Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS, Damko E, Moquin D, Walz T, McDermott A, Chan FK, Wu H

The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis.

Cell. 2012 Jul 20;150(2):339-50. PubMed: 22817896

Elena Galea on No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers

COMMENT The finding that immunotherapy against amyloid-β may work in ApoE3 carriers but not in ApoE4 carriers supports that ApoE4 inflicts damage to the brain in a manner independent of amyloid-β. Therefore, combination therapy targeting amyloid-β AND ApoE4 appea

Allen Roses on TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease.

COMMENT When we first saw this paper published, we noted that one of the PCR primers was identical to that published in our primary paper; the other primer had single base deletion. The remaining sequence facilitated their novel method, but that failed to determi

Lucy Crompton

Q&A With Roche’s CNS Leader Luca Santarelli

CONFERENCE COVERAGE 2012-07-25 Conference Coverage At the Alzheimer’s Association International Conference held 14-19 July 2012 in Vancouver, Canada, Gabrielle Strobel met up with Luca Santarelli, Senior Vice President and Head of Neuroscience at Hoffmann-La Roche. Santarelli is perhap

PAPER Tosatto L, Andrighetti AO, Plotegher N, Antonini V, Tessari I, Ricci L, Bubacco L, Dalla Serra M

Alpha-synuclein pore forming activity upon membrane association.

Biochim Biophys Acta. 2012 Nov;1818(11):2876-83. PubMed: 22820150